Structural approach to the aging of phosphylated cholinesterases

Chemico-Biological Interactions

Volumn 187, Issue 1-3, 2010, Pages 157-162

  Masson, Patrick ^a,b,c   Nachon, Florian ^a   Lockridge, Oksana ^c  

^a CENTRE DE RECHERCHES   (France)

^b Molecular Biophysics Laboratory   (France)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Aging; Cholinesterase; Organophosphorus compounds

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE; HISTIDINE; MALATHION; ORGANIC SOLVENT; PHOSPHORAMIDIC ACID DERIVATIVE; TABUN; UREA;

ARTICLE; CHOLINESTERASE INHIBITION; CONFORMATIONAL TRANSITION; CONJUGATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEALKYLATION; DEAMINATION; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME DENATURATION; ENZYME STABILITY; ENZYME STRUCTURE; PROTEIN CLEAVAGE;

EID: 77955513808     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.03.027     Document Type: Article

References (75)

1. Toxicology of Organophosphate and Carbamate Compounds 2006, Academic Press-Elsevier, Amsterdam, xvi+763 pp. R.C. Gupta (Ed.).
2. Handbook of Toxicology of Chemical Warfare Agents 2009, Academic Press-Elsevier, Amsterdam, xviii+1147 pp. R.C. Gupta (Ed.).
3. Eddleston M., Buckley N.A., Eyer P., Dawson A.H. Management of acute organophosphorus pesticide poisoning. Lancet 2008, 371:597-607.
4. Nicolet Y., Lockridge O., Masson P., Fontecilla-Camp J.C., Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 2003, 278:41141-41147.
5. Saxena A., Redman A.M., Jiang X., Lockridge O., Doctor B.P. Differences in active site gorge dimensions of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 1997, 36:14642-14651.
6. Jarv J. Stereochemical aspects of cholinesterase catalysis. Bioorg. Chem. 1984, 12:259-278.
7. Maxwell D.M., Brecht K.M., Koplovitz I.M., Sweeney R.E. Acetylcholinesterase inhibition: does it explain the toxicity of organophosphates?. Arch. Toxicol. 2006, 80:756-760.
8. Casida J.E., Quistad G.B. Organophophate toxicology: safety aspects of nonacetylcholinesterase secondary targets. Chem. Res. Toxicol. 2004, 17:983-998.
9. L.M. Schopfer, H. Grigoryan, B. Li, F. Nachon, P. Masson, O. Lockridge, Mass spectral characterization of organophosphate-labeled tyrosine-containing peptides: characteristic mass fragments and a new binding motif for organophosphates, J. Chromatogr. B, in press.
10. Worek F., Aurbek N., Herkert N.M., John H., Eddleston M., Eyer P., Thiermann H. Evaluation of medical countermeasures against organophosphorus compounds: the value of experimental data and computer simulations. Chem. -Biol. Interact. 2010, 187:259-264.
11. Eyer P., Worek F., Thiermann H., Eddleston M. Paradox findings may challenge orthodox reasoning in acute organophosphate poisoning. Chem. -Biol. Interact. 2010, 187:270-278.
12. Antonijevic B., Stojiljkovic M.P. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin. Med. Res. 2007, 5:71-82.
13. Jokanovic M., Prostran M. Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. Curr. Med. Chem. 2009, 16:2177-2188.
14. Kovarik Z., Katalinic M., Sinko G., Binder J., Holas O., Jung Y.-S., Musilova L., Jun D., Kuca K. Pseudo-catalytic scavenging: searching for a suitable reactivator of phosphorylated butyrylcholinesterase. Chem. -Biol. Interact. 2010, 187:167-171.
15. Masson P., Lockridge O. Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior. Arch. Biochem. Biophys. 2010, 494:107-120.
16. Fleming C.D., Edwards C.C., Kirby S.D., Maxwell D.M., Potter P.M., Cerasoli D.M., Redinbo M.R. Crystal structure of human carboxylesterase 1 in covalent complexes with the chemical warfare agents soman and tabun. Biochemistry 2007, 46:5063-5071.
17. Epstein T.M., Samanta U., Kirby S.D., Cerasoli D.M., Bahnson B.J. Crystal structures of brain group-VIII phospholipase A2 in non aged complexes with the organophosphorus nerve agents soman and sarin. Biochemistry 2009, 48:3425-3435.
18. Harel M., Su C.T., Frolow F., Ashani Y., Silman I., Sussman J.L. Refined crystal structures of " aged" and " non-aged" organophosphoryl conjugates of gama-chymotrypsin. J. Mol. Biol. 1991, 221:909-918.
19. Strumeyer D.H., White W.N., Koshland D.E. Role of serine in chymotrypsin action. Conversion of the active serine to dehydroalanine. Proc. Natl. Acad. U.S.A. 1963, 50:931-935.
20. Gilley C., McDonald M., Nachon F., Schopfer L.M., Zhang J., Cashman J.R., Lockridge O. Nerve agent analogues that produce authentic soman, sarin, tabun, and cyclohexyl methylphosphonate-modified human butyrylcholinesterase. Biochemistry 2009, 22:1680-1688.
21. Shafferman A., Ordentlich A., Barak D., Stein D., Ariel N., Velan B. Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre. Biochem. J. 1996, 318:833-840.
22. Worek F., Eyer P., Szinicz L. Inhibition, reactivation and aging kinetics of cyclohexylmethylphosphonofluoridate-inhibited human aceylcholinesterases. Arch. Toxicol. 1998, 72:580-587.
23. Aurbek N., Thierman H., Szinicz L., Eyer P., Worek F. Analysis of inhibition, reactivation and aging kinetics of highly toxic organophosphorus compounds with human and pig acetylcholinesterase. Toxicology 2006, 224:91-99.
24. Kovach I.M. Stereochemistry and secondary reactions in the irreversible inhibition of serine hydrolases by organophosphorus compounds. J. Phys. Org. Chem. 2004, 17:602-614.
25. Beauregard G., Lum J., Roufogalis B.D. Effect of histidine modification on the aging of organophosphate-inhibited acetylcholinesterase. Biochem. Pharmacol. 1981, 30:2915-2920.
26. Saxena A., Doctor B.P., Maxwell D.M., Lenz D.E., Radic Z., Taylor P. The role of glutamate-199 in the aging of cholinesterase. Biochem. Biophys. Res. Commun. 1993, 197:343-349.
27. Barak D., Ordentlich A., Segal Y., Velan B., Benschop H.P., De Jong L.P.A., Shafferman A. Carbocation-mediated processes in biocatalysts. Contribution of aromatic moieties. J. Am. Chem. Soc. 1997, 119:3157-3158.
28. Masson P., Fortier P.-L., Albaret C., Froment M.-T., Bartels C., Lockridge O. Aging of diisopropyl-phosphorylated human butyrylcholinesterase. Biochem. J. 1997, 327:601-607.
29. Nachon F., Asojo O.A., Borgstahl G.E.O., Masson P., Lockridge O. Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging. Biochemistry 2005, 44:1154-1162.
30. Carletti E., Li H., Li B., Ekstrom F., Nicolet Y., Loiodice M., Gillon E., Froment M.T., Lockridge O., Schopfer L.M., Masson P., Nachon F. Aging of cholinesterases phosphylated by tabun proceeds through O-dealkylation. J. Am. Chem. Soc. 2008, 130:16011-16020.
31. Millard C.B., Koellner G., Ordentlich A., Shafferman A., Silman I., Sussman J.L. Reaction products of acetylcholinesterase and VX reveal a mobile histidine in the catalytic triad. J. Am. Chem. Soc. 1999, 121:9883-9884.
32. Ekstrom F., Akfur C., Tunemalm A.-K., Lundberg S. Structural changes in phenylalanine 338 and histidine 447 revealed by the crystal structures of tabun-inhibited murine acetylcholinesterase. Biochemistry 2006, 45:74-81.
33. Massiah M.A., Viragh C., Reddy P.M., Kovach I.M., Johnson J., Rosenberry T.L., Mildvan A. Short, strong hydrogen bond at the active site of human acetylcholinesterase: proton NMR studies. Biochemistry 2001, 40:5682-5690.
34. Masson P., Froment M.T., Bartels C.F., Lockridge O. Importance of aspartate-70 in organophosphate inhibition, oxime reactivation and aging of human butyrylcholinesterase. Biochem. J. 1997, 325:53-61.
35. Masson P. Double-mutant thermodynamic cycles under high hydrostatic pressure. Advances in High Pressure Bioscience and Biotechnology II 2003, 61-68. Springer, Berlin. R. Winter (Ed.).
36. Masson P., Cléry C., Guerra P., Redslob A., Albaret C., Fortier P.L. Hydration change during the aging of phosphorylated human butyrylcholinesterase: importance of residues aspartate-70 and glutamate-197 in the water network as probed by hydrostatic and osmotic pressures. Biochem. J. 1999, 343:361-369.
37. Sanson B., Nachon F., Colletier J.P., Froment M.T., Toker L., Greenblatt H.M., Sussman J.L., Ashani Y., Masson P., Silman I., Weik M. Crystallographic snapshots of nonaged and aged conjugates of soman with acetylcholinesterase, and of a ternary complex of the aged conjugate with pralidoxime. J. Med. Chem. 2009, 52:7593-7603.
38. Smith T.E., Usdin E. Formation of nonreactivatible isopropylmethylphosphonofluoridate-inhibited acetylcholinesterase. Biochemistry 1966, 5:2914-2918.
39. Michell H.O., Hackley B.E., Berkowitz L., List G., Hackley E.B., Gillilan W., Pankau M. Formation of nonreactivatible isopropylmethylphosphonofluoridate-inhibited acetylcholinesterase. Arch. Biochem. Biophys. 1967, 212:29-34.
40. Viragh C., Kovach I.M., Pannell L. Small molecular products of dealkylation in soman-inhibited electric eel acetylcholinesterase. Biochemistry 1999, 38:9557-9561.
41. Viragh C., Akhmetshin R., Kovach I.M., Broomfield C. Unique push-pull mechanism of dealkylation in soman-inhibited cholinesterases. Biochemistry 1997, 36:8243-8252.
42. Shafferman A., Ordentlich A., Barak D., Stein D., Ariel N., Velan B. Aging of somany-acetylcholinesterase adducts: facts and models. Biochem. J. 1997, 324:996-998.
43. Li H., Schopfer L.M., Nachon F., Froment M.T., Masson P., Lockridge O. Aging pathways for organophosphate-inhibited human butyrylcholinesterase, including novel pathways for isomalathion, resolved by mass spectrometry. Toxicol. Sci. 2007, 100:136-145.
44. Hobbiger F. Cholinesterases and Anticholinesterase Agents 1963, 941. Springer, Berlin. G.B. Koelle (Ed.).
45. Harris L.W., Fleicher J.H., Clark J., Cliff W.J. Dealkylation and loss of capacity for reactivation of cholinesterase inhibited by sarin. Science 1966, 154:404-407.
46. Kirby A.J., Younas M. The reactivity of phosphate esters. Reactions of diesters with nucleophiles. J. Chem. Soc. B 1970, 1165-1172.
47. Behrman E.J., Biallas M.J., Brass H.J., Edwards J.O., Isaks M. Reactions of phosphonic acid esters with nucleophiles. I. Hydrolysis. J. Org. Chem. 1970, 35:3063-3069.
48. Behrman E.J., Biallas M.J., Brass H.J., Edwards J.O., Isaks M. Reactions of phosphonic acid esters with nucleophiles. II. Survey of nucleophiles reacting with p-nitrophenyl methylphosphonate anion. J. Org. Chem. 1970, 35:3069-3075.
49. Segall Y., Waysbrort D., Barak D., Ariel N., Doctor B.P., Grunwald J., Ashani Y. Direct observation and elucidation of the structures of aged and nonaged phosphorylated cholinesterases by 31P NMR spectroscopy. Biochemistry 1993, 32:13350-13441.
50. Amitai G., Ashani Y., Gafni A., Silman I. Novel pyrene-containing organophosphates as fluorescent probes for studying aging-induced conformational changes in organophosphate-inhibited acetylcholinesterase. Biochemistry 1982, 21:2060-2069.
51. Berman H.A., Decker M.M. Kinetic, equilibrium, and spectroscopic studies on dealkylation (" aging" ) of alkyl organophosphonyl acetylcholinesterase. Electrostatic control of enzyme topography. J. Biol. Chem. 1986, 261:10646-10652.
52. Masson P., Marnot B., Lombard J.Y., Morelis P. Electrophoretic study of aged butyrylcholinesterase after inhibition by soman. Biochimie 1984, 66:235-249.
53. Masson P., Goasdoue J.L. Evidence that the conformational stability of " aged" organophosphate-inhibited cholinesterase is altered. Biochim. Biophys. Acta 1986, 869:304-313.
54. Masson P., Gouet P., Clery C. Pressure and propylene carbonate denaturation of native and " aged" phosphorylated cholinesterase. J. Mol. Biol. 1994, 328:466-478.
55. Ashani Y., Gentry M.K., Doctor B.P. Differences in conformational stability between native and phosphorylated acetylcholinesterase as evidenced by monoclonal antibody. Biochemistry 1990, 29:2456-2463.
56. Gabel F., Masson P., Froment M.T., Doctor B.P., Saxena A., Silman I., Zaccai G., Weik M. Direct correlation between molecular dynamics and enzymatic stability: a comparative neutron scattering study of native human butyrylcholinesterase and its " aged" soman conjugate. Biophys. J. 2009, 96:1489-1494.
57. Carletti E., Aurbek N., Gillon E., Loiodice M., Nicolet Y., Fontecilla-Camps J.C., Masson P., Thiermann H., Nachon F., Worek F. Structure-activity analysis of aging and reactivation of human butyrylcholinesterase inhibited by analogues of tabun. Biochem. J. 2009, 421:97-106.
58. Schoene K. Aging of soman-inhibited acetylcholinesterase: inhibitors and accelerators. Biochim. Biophys. Acta 1978, 525:468-471.
59. Schoene K., Steinhanses J., Watermann A. Aging of soman-inhibited acetylcholinesterase. pH-rate profiles an temperature dependence in absence and in presence of effectors. Biochim. Biophys. Acta 1980, 616:384-388.
60. Stalc A., Sentjurc M. A contribution to the mechanism of action of SAD-128. Biochem. Pharmacol. 1990, 40:2511-2517.
61. Dawson R.M., Dowling M.H., Poretski M. Assessment of the competition between tacrine and gallamine for binding sites on acetylcholinesterase. Neurochem. Int. 1991, 19:125-133.
62. Puu G. Ketamine protects acetylcholinesterase against in vitro inhibition by sarin. Biochem. Pharmacol. 1988, 37:969-970.
63. Dawson R.M. Tacrine slows the rate of ageing of sarin-inhibited acetylcholinesterase. Neurosci. Lett. 1989, 100:625-634.
64. Johnson J.L., Cusack B., Hughes T.F., McCullough E.H., Fauq A., Romanovskis P., Spatola A.F., Rosenberry T.L. Inhibitors tethered near the acetylcholinesterase active site serve as molecular rulers of the peripheral and acylation sites. J. Biol. Chem. 2003, 278:38948-38955.
65. Zheng X., Baker N., Marshall G.R., Rosenberry T.L., Sept D. Cyclic peptides as prophylactic agents for acetylcholinesterase. 10th International Meeting on Cholinesterases 2009, 41.
66. Taylor P., Kovarik Z., Reiner E., Radic Z. Acetylcholinesterase: converting a vulnerable target to a template for antidotes and detection of inhibitor exposure. Toxicology 2007, 233:70-78.
67. Mizutani M.Y., Itai A. Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. J. Med. Chem. 2004, 47:4818-4828.
68. Ekström F.J., Astot C., Pang Y.P. Novel nerve-agent antidote design based on crystallographic and mass spectrometric analyses of tabun-conjugated acetylcholinesterase in complex with antidotes. Clin. Pharmacol. Ther. 2007, 82:282-293.
69. Hörnberg A., Artursson E., Warne R., Pang Y.-P., Ekström F. Crystal structure of oxime-bound fenamiphos-acetylcholinesterase: reactivation involving flipping of the His447 ring to form a reactive Glu334-His447-oxime triad. Biochem. Pharmacol. 2010, 79:507-515.
70. Saxena A., Sun W., Luo C., Myers T.M., Koplovitz I., Lenz D.E., Doctor B.P. Bioscavenger for protection from toxicity of organophosphorus compounds. J. Mol. Neurosci. 2006, 30:145-148.
71. Masson P., Nachon F., Broomfield C.A., Lenz D.E., Verdier L., Schopfer L.M., Lockridge O. A collaborative endeavor to design cholinesterase-based catalytic scavengers against toxic organophosphorus esters. Chem. Biol. Interact. 2008, 175:273-280.
72. Saxena A., Maxwell D.M., Quinn D.M., Radic Z., Taylor P., Doctor B.P. Mutant acetylcholinesterases as potential detoxification agents for organophosphate poisoning. Biochem. Pharmacol. 1997, 54:269-274.
73. Kovarik Z., Radic Z., Berman H.A., Taylor P. Mutation of acetylcholinesterase to enhance oxime-assisted catalytic turnover of methylphosphonates. Toxicology 2007, 233:79-84.
74. Mazor O., Cohen O., Kronman C., Raveh L., Stein D., Ordentlich A., Shafferman A. Aging-resistant organophosphate bioscavenger based on polyethylene glycol-conjugated F338A human acetylcholinesterase. Mol. Pharmacol. 2008, 74:755-763.
75. Chronman C., Cohen O., Mazor O., Ordentlich A., Raveh L., Velan B., Shafferman A. Next generation of OP-bioscangers: a circulatory long-lived 4-PEG hypolysine mutant of F338A-huAChE with optimal pharmacokinetics and pseudo-catalytic characteristics. Chem. -Biol. Interact. 2010, 187:253-258.